There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Genocea Biosciences (GNCA – Research Report), Biospecifics Technologies Corp (BSTC – Research Report) and Constellation Pharmaceuticals Inc (CNST – Research Report) with bullish sentiments.
Genocea Biosciences (GNCA)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Genocea Biosciences today and set a price target of $5.75. The company’s shares opened today at $0.62.
“Valuation and risks to price target achievement. We reiterate our Buy rating and $5.75 price target. Our valuation is based on our clinical net present value (NPV) model, which is currently driven by the company’s lead asset, GEN-009. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile.”
According to TipRanks.com, Pantginis is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -13.7% and a 28.9% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Iovance Biotherapeutics Inc, and Checkpoint Therapeutics Inc.
Genocea Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $3.88.
Biospecifics Technologies Corp (BSTC)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Biospecifics Technologies Corp, with a price target of $85. The company’s shares opened today at $64.52.
“We note that this is the highest quarterly XIAFLEX royalty revenue ever recorded by the company, driven primarily by the underlying volume growth in both the Contracture indications. Net income was $6.2M during the fourth quarter, or $0.84 per diluted share, beating our estimated EPS of $0.82 per share. For full-year 2018, total revenue was $33.0M; net income was $20.1M, or $2.73 per diluted share. Importantly, Endo (ENDP; not rated) management expects XIAFLEX growth in the mid-to-high teens percentage range for 2019, indicating further growth in royalty revenue to BioSpecifics. Our 2019 revenue and EPS estimates for BioSpecifics are $37.4M and $3.01 per share, respectively. In the wake of this update, we reiterate our Buy rating and $85 price target.”
According to TipRanks.com, Selvaraju is a 3-star analyst with an average return of 1.4% and a 35.8% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as EyePoint Pharmaceuticals Inc, Bausch Health Companies Inc, and Fennec Pharmaceuticals Inc.
Currently, the analyst consensus on Biospecifics Technologies Corp is a Moderate Buy with an average price target of $85.
Constellation Pharmaceuticals Inc (CNST)
In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Constellation Pharmaceuticals Inc, with a price target of $18. The company’s shares opened today at $13.29, close to its 52-week high of $14.04.
According to TipRanks.com, Fein is a 5-star analyst with an average return of 9.4% and a 48.8% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Proteostasis Therapeutics Inc, and ACADIA Pharmaceuticals Inc.
Constellation Pharmaceuticals Inc has an analyst consensus of Strong Buy, with a price target consensus of $17.67, which is a 33.0% upside from current levels. In a report issued on March 20, Oppenheimer also assigned a Buy rating to the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.